In vitro susceptibility of varicella-zoster virus to acyclovir
about
Varicella-zoster virusUse of an enzyme-linked immunosorbent assay performed directly on fixed infected cell monolayers for evaluating drugs against varicella-zoster virusAntiviral drug resistance: mechanisms and clinical implications6-Methoxypurine arabinoside as a selective and potent inhibitor of varicella-zoster virusMode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virusPhosphorylation of beta-D-ribosylbenzimidazoles is not required for activity against human cytomegalovirusAnti-human immunodeficiency virus agent 3'-azido-3'-deoxythymidine inhibits replication of Epstein-Barr virusInhibition of varicella-zoster virus-induced DNA polymerase by a new guanosine analog, 9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine triphosphateAcyclic guanosine analogs as inhibitors of human cytomegalovirusAntiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell cultureInhibitory effects of antiherpesviral thymidine analogs against varicella-zoster virusIn vitro susceptibility of varicella-zoster virus to E-5-(2-bromovinyl)-2'-deoxyuridine and related compoundsAnalysis of phosphorylation pathways of antiherpesvirus nucleosides by varicella-zoster virus-specific enzymesInhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene productTri-partite complex for axonal transport drug delivery achieves pharmacological effect.Antiviral selection in the management of acute retinal necrosis.Valacyclovir and acyclovir pharmacokinetics in immunocompromised children.2-Acetylpyridine 5-[(dimethylamino)thiocarbonyl]-thiocarbonohydrazone (A1110U), a potent inactivator of ribonucleotide reductases of herpes simplex and varicella-zoster viruses and a potentiator of acyclovir.Acyclovir: discovery, mechanism of action, and selectivity.Pharmacokinetics and safety of multiple-dose valaciclovir in geriatric volunteers with and without concomitant diuretic therapy.Acyclovir treatment of experimental simian varicella infection of monkeysUptake, distribution, and anabolism of acyclovir in herpes simplex virus-infected miceEffect of acyclovir and interferon on human hematopoietic progenitor cells.Effect of several antiviral agents on human lymphocyte functions and marrow progenitor cell proliferation.Susceptibility of vaccine strains of varicella-zoster virus to antiviral compoundsAntiviral therapy: current concepts and practices6-Deoxyacyclovir: a xanthine oxidase-activated prodrug of acyclovir.Valacyclovir as Initial Treatment for Acute Retinal Necrosis: A Pharmacokinetic Modeling and Simulation Study.Metabolism and pharmacokinetics of the anti-varicella-zoster virus agent 6-dimethylaminopurine arabinoside.Advances in antiviral therapy: acyclovir.6-N-substituted derivatives of adenine arabinoside as selective inhibitors of varicella-zoster virus.Selective anabolism of 6-methoxypurine arabinoside in varicella-zoster virus-infected cells.Mutant varicella-zoster virus thymidine kinase: correlation of clinical resistance and enzyme impairment.Antiherpes drugs: promises and pitfalls.Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications.Structure-activity relationships and conformational features of antiherpetic pyrimidine and purine nucleoside analogues. A review.New antivirals with activity against varicella-zoster virus.Management of ophthalmic zoster.Acyclovir: is it an effective virostatic agent for orofacial infections?Acyclovir for the prevention and treatment of varicella zoster in children, adolescents and pregnancy.
P2860
Q24683811-39936CCF-1F8F-4B35-B465-2ACB1470BF8FQ27478097-8DB00751-2075-4A5B-8587-24ABFC1A00BCQ28282376-42F7D6AE-CD6F-4C95-AEBD-848B05642DC5Q28321395-3CCEF55B-7EE6-4544-818E-99013917C668Q28327167-BCE469E4-9FA9-496B-8AE6-9B8C35C311F9Q28345180-C54A12F2-3E7D-488B-AC86-188C99117FA8Q28359820-9CB568B0-FD63-417F-B0F2-E563012E4C6AQ28359883-ED2BFE66-E965-4BEE-915C-B2D4954A8F40Q28360560-714C2A45-7A0E-4A7F-BD1C-7A8C73A32B10Q28361902-1FBD35D2-F11A-46F1-AD54-2B9F0FE2A56BQ28366145-14601936-C81B-4EF2-9250-AA9909E339B8Q28366155-912090B7-F53F-4E1F-8846-FE5354DDE5F0Q28379207-7D187EBA-49FC-484C-833F-4FBD766D30AAQ28379289-53FA32A0-580B-425C-BBED-CA8273A37E8EQ33525199-B6D28202-EAA8-4CBC-8036-000BBD3FE3FEQ33644146-D62BAF54-E563-4250-AF24-A3B58975A2B5Q33776931-8A20F121-0DCF-40B5-AA72-AF8175DC4E7FQ33836051-EF7DEF52-9CF9-4809-ACBD-769FF07F618AQ34345105-5F96B19A-2F99-4E38-911F-6A89BA637622Q35121549-AE828426-DA98-40F9-A163-5FC21436F5E0Q35671376-0E99806F-FCFA-4D53-89AE-17E0B0779E0EQ35673064-E71BECAA-145C-4653-A1AC-0768E83B4703Q35673321-874D644F-B211-4282-B149-1924F649E8D2Q35740490-CAC08B39-693F-4A3B-AA66-D39750D34D05Q35758745-5913E1AC-7C93-48E7-BB80-8BB98B6496C7Q36070394-7CBE6C20-9EF9-42FF-B4A4-8ED9ACCE6DA8Q36261735-FBE3944D-CE31-4B0E-9620-D90720F73B35Q38867550-A1C581CE-FF97-4852-82FB-A2F4BC6001BCQ39867911-8F34A4F0-A7D3-46E9-86AC-D9360F13A88FQ40079186-4AAE94C4-62C4-4A11-BE6D-190610C4D657Q40086870-895F3B80-2395-4CFE-96A6-DFA17F955AD3Q40087739-56FAC936-AFFD-4981-A8E7-A1BB25675393Q40115283-997C66CC-E523-4982-B755-F4B64409C4E9Q40142222-A371C804-09CA-4604-A5BF-03A084823CD0Q40164352-BF0D7340-2FB4-42B1-91AB-47C3A613A95CQ40672683-DF2C9018-6CF7-45E2-8D88-27492CA2B5D2Q40753536-E813BBD1-90C9-48EB-AF08-3F29769C9CA5Q40782553-5061619B-9330-4444-92B7-9C813D71FDB3Q40811393-B1E8582A-5DB7-4578-953E-053F46F1B1B7Q41128328-A32D2778-EC8F-47D9-91AD-36B0E5639538
P2860
In vitro susceptibility of varicella-zoster virus to acyclovir
description
1980 nî lūn-bûn
@nan
1980 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1980 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1980年の論文
@ja
1980年論文
@yue
1980年論文
@zh-hant
1980年論文
@zh-hk
1980年論文
@zh-mo
1980年論文
@zh-tw
1980年论文
@wuu
name
In vitro susceptibility of varicella-zoster virus to acyclovir
@ast
In vitro susceptibility of varicella-zoster virus to acyclovir
@en
In vitro susceptibility of varicella-zoster virus to acyclovir
@nl
type
label
In vitro susceptibility of varicella-zoster virus to acyclovir
@ast
In vitro susceptibility of varicella-zoster virus to acyclovir
@en
In vitro susceptibility of varicella-zoster virus to acyclovir
@nl
prefLabel
In vitro susceptibility of varicella-zoster virus to acyclovir
@ast
In vitro susceptibility of varicella-zoster virus to acyclovir
@en
In vitro susceptibility of varicella-zoster virus to acyclovir
@nl
P2860
P356
P1476
In vitro susceptibility of varicella-zoster virus to acyclovir
@en
P2093
P2860
P356
10.1128/AAC.18.3.443
P407
P577
1980-09-01T00:00:00Z